Chemical Component Summary

NameTOLRESTAT
Identifiers2-[[6-methoxy-5-(trifluoromethyl)naphthalen-1-yl]carbothioyl-methyl-amino]ethanoic acid
FormulaC16 H14 F3 N O3 S
Molecular Weight357.35
TypeNON-POLYMER
Isomeric SMILESCOc1ccc2c(cccc2c1C(F)(F)F)C(=S)N(C)CC(O)=O
InChIInChI=1S/C16H14F3NO3S/c1-20(8-13(21)22)15(24)11-5-3-4-10-9(11)6-7-12(23-2)14(10)16(17,18)19/h3-7H,8H2,1-2H3,(H,21,22)
InChIKeyLUBHDINQXIHVLS-UHFFFAOYSA-N

Chemical Details

Formal Charge0
Atom Count38
Chiral Atom Count0
Chiral Atomsn/a
Bond Count39
Aromatic Bond Count11
Leaving Atomsn/a

Drug Info: DrugBank

DrugBank IDDB02383 Different stereochemistry
NameTolrestat
Groupswithdrawn
DescriptionTolrestat (INN) (AY-27773) is an aldose reductase inhibitor which was approved for the control of certain diabetic complications. While it was approved for marketed in several countries, it failed a Phase III trial in the U.S. due to toxicity and never received FDA approval. It was discontinued by Wyeth in 1997 because of the risk of severe liver toxicity and death. It was sold under the tradename Alredase. [Wikipedia]
Brand NamesAlredase
Affected OrganismHumans and other mammals
IndicationFor the pharmacological control of certain diabetic complications.
Categories
  • Aldehyde Reductase, antagonists & inhibitors
  • Aldose Reductase Inhibitors
  • Alimentary Tract and Metabolism
  • Chemical Actions and Uses
  • Drugs Used in Diabetes
ATC-CodeA10XA01
CAS number82964-04-3
Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS. Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID:21059682